Quetiapine Tablet, Film Coated, Extended Release
Product Images NDC 68180-616

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Quetiapine (NDC 68180-616). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 01

Chemical structure of quetiapine shown alongside the structure of an associated compound, likely a counter ion or salt form, depicted with molecular bonds and atom groups.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 02

A Kaplan-Meier curve graph showing time to schizophrenic relapse over 7 months. The y-axis represents the proportion of patients with relapse (%) from 0 to 100, and the x-axis represents time in months. Two curves compare placebo (PLA) and Quetiapine extended-release (QTP XR), indicating differences in relapse rates over time.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 03

A Kaplan-Meier curve graph showing the time to recurrence of a mood event in a study. The x-axis represents time in weeks, while the y-axis indicates the proportion of patients with relapse as a percentage. Two curves are displayed, comparing QTP + LIWAL versus PLA + LIWAL treatment groups.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 04

Kaplan-Meier curves depicting time to recurrence of a mood event over approximately 100 weeks. The y-axis shows the proportion of patients with relapse in percentage, and the x-axis shows time in weeks. Two curves represent treatment groups, one with Quetiapine plus LiVal and the other with placebo plus LiVal.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 05

Label for Quetiapine Extended-Release Tablets USP 50 mg by Lupin Pharmaceuticals, Inc. The tablet is film-coated with 50 mg strength, in a bottle containing 60 tablets. Label instructs to swallow whole and mentions usual dosage as once daily, with storage guidelines and manufacturer information included.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 06

Quetiapine Extended-Release Tablets USP 150 mg film-coated tablet label. The label indicates once-daily oral administration and highlights the pharmacist's instruction to dispense the medication guide. The package contains 60 tablets and is manufactured by Lupin Pharmaceuticals, Inc. with manufacturing in India. Storage and usage warnings are present, along with a barcode and QR code for medication guide access.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 07

Label for Quetiapine Extended-Release Tablets USP 200 mg by Lupin Pharmaceuticals, Inc. The film-coated tablets are for oral use with a once-daily dose. The label includes dispensing instructions, storage conditions, manufacturer details, a barcode, and package count of 60 tablets.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 08

Label for Quetiapine Extended-Release Tablets USP 300 mg, oral film-coated extended-release tablets. The label shows dosing as once daily, contains 60 tablets per bottle, and is manufactured by Lupin Pharmaceuticals, Inc. Storage instructions and a barcode are also visible.*

FDA Label Image

E3429a09 4870 4e48 9a35 512236e39832 09

Quetiapine Extended-Release Tablets USP 400 mg film-coated oral tablets label by Lupin Pharmaceuticals, Inc. The label indicates a 60 tablet count with instructions for once daily dosage. Includes storage information, warning to keep out of reach of children, and manufacturer details for Lupin Pharmaceuticals, Inc. and Lupin Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.